Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer
Paolo Tarantino, Se-Eun Kim, Melissa E. Hughes, Ross J. Kusmick et autres
Trastuzumab deruxtecan (T-DXd) is commonly used for treating metastatic breast cancer (MBC); however, traditional HER2 immunohistochemistry has largely failed to predict T-DXd activity. We reviewed survival outcomes and tested the reliability of multiple HER2 quantitative assays in predicting T-DXd's performance among 191 …
us, it, es (code pays fourni par la source)
2 citations
npj Precision Oncology